OA12697A - HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis. - Google Patents

HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis. Download PDF

Info

Publication number: OA12697A
Authority: OA; OAPI
Prior art keywords: group; carbocyclic; aliphatic; heterocyclic; aliphatic group
Prior art date: 2001-06-11

Application number

OA1200300323A

Other languages

English (en)

Inventor

Stacie S Canon-Koch

Therese N Alexander

Mark Barvian

Gary Bolton

Fredrick E Boyer

Benjamin J Burke

Tod Holler

Original Assignee

Agouron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-11

Filing date

2002-06-11

Publication date

2006-06-21

2002-06-11 Application filed by Agouron Pharma filed Critical Agouron Pharma

2006-06-21 Publication of OA12697A publication Critical patent/OA12697A/en

Links

239000000203 mixture Substances 0.000 title claims 3
239000004030 hiv protease inhibitor Substances 0.000 title claims 2
230000015572 biosynthetic process Effects 0.000 title 1
239000000463 material Substances 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract 44
239000008194 pharmaceutical composition Substances 0.000 claims abstract 5
108010010369 HIV Protease Proteins 0.000 claims abstract 4
125000001931 aliphatic group Chemical group 0.000 claims 137
125000000623 heterocyclic group Chemical group 0.000 claims 92
125000002837 carbocyclic group Chemical group 0.000 claims 88
125000001424 substituent group Chemical group 0.000 claims 54
125000005843 halogen group Chemical group 0.000 claims 45
125000000217 alkyl group Chemical group 0.000 claims 43
150000003839 salts Chemical class 0.000 claims 37
239000002207 metabolite Substances 0.000 claims 36
239000000651 prodrug Substances 0.000 claims 36
229940002612 prodrug Drugs 0.000 claims 36
239000012453 solvate Substances 0.000 claims 34
-1 nitro, amino Chemical group 0.000 claims 31
229920006395 saturated elastomer Polymers 0.000 claims 31
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 25
125000003710 aryl alkyl group Chemical group 0.000 claims 19
125000001188 haloalkyl group Chemical group 0.000 claims 17
229910052736 halogen Inorganic materials 0.000 claims 17
150000002367 halogens Chemical class 0.000 claims 17
125000003545 alkoxy group Chemical group 0.000 claims 16
125000004414 alkyl thio group Chemical group 0.000 claims 16
125000004429 atom Chemical group 0.000 claims 16
125000004093 cyano group Chemical group *C#N 0.000 claims 16
125000004453 alkoxycarbonyl group Chemical group 0.000 claims 15
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 15
125000003282 alkyl amino group Chemical group 0.000 claims 15
125000004670 alkyl amino thio carbonyl group Chemical group 0.000 claims 15
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 15
125000004448 alkyl carbonyl group Chemical group 0.000 claims 15
125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 15
125000004647 alkyl sulfenyl group Chemical group 0.000 claims 15
125000004390 alkyl sulfonyl group Chemical group 0.000 claims 15
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 15
125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 15
125000005530 alkylenedioxy group Chemical group 0.000 claims 15
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 15
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 15
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 15
125000003396 thiol group Chemical class [H]S* 0.000 claims 15
125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 14
125000004671 dialkylaminothiocarbonyl group Chemical group 0.000 claims 14
229910052799 carbon Inorganic materials 0.000 claims 13
125000004663 dialkyl amino group Chemical group 0.000 claims 13
125000003342 alkenyl group Chemical group 0.000 claims 12
229910052760 oxygen Inorganic materials 0.000 claims 10
101150009274 nhr-1 gene Proteins 0.000 claims 9
125000000304 alkynyl group Chemical group 0.000 claims 8
229910052757 nitrogen Inorganic materials 0.000 claims 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
125000003118 aryl group Chemical group 0.000 claims 6
125000000392 cycloalkenyl group Chemical group 0.000 claims 6
125000001072 heteroaryl group Chemical group 0.000 claims 6
125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
229910052717 sulfur Inorganic materials 0.000 claims 6
125000004446 heteroarylalkyl group Chemical group 0.000 claims 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
125000001620 monocyclic carbocycle group Chemical group 0.000 claims 5
208000030507 AIDS Diseases 0.000 claims 4
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
125000000753 cycloalkyl group Chemical group 0.000 claims 4
125000004366 heterocycloalkenyl group Chemical group 0.000 claims 4
238000000034 method Methods 0.000 claims 4
239000003443 antiviral agent Substances 0.000 claims 3
125000005018 aryl alkenyl group Chemical group 0.000 claims 3
125000005015 aryl alkynyl group Chemical group 0.000 claims 3
239000003795 chemical substances by application Substances 0.000 claims 3
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 3
125000000165 tricyclic carbocycle group Chemical group 0.000 claims 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
208000031886 HIV Infections Diseases 0.000 claims 2
108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 2
208000037357 HIV infectious disease Diseases 0.000 claims 2
125000005133 alkynyloxy group Chemical group 0.000 claims 2
229960005475 antiinfective agent Drugs 0.000 claims 2
239000004599 antimicrobial Substances 0.000 claims 2
125000004432 carbon atom Chemical group C* 0.000 claims 2
125000005356 cycloalkylalkenyl group Chemical group 0.000 claims 2
125000005357 cycloalkylalkynyl group Chemical group 0.000 claims 2
230000000694 effects Effects 0.000 claims 2
125000004438 haloalkoxy group Chemical group 0.000 claims 2
125000004447 heteroarylalkenyl group Chemical group 0.000 claims 2
125000005312 heteroarylalkynyl group Chemical group 0.000 claims 2
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
239000002955 immunomodulating agent Substances 0.000 claims 2
229940121354 immunomodulator Drugs 0.000 claims 2
125000000842 isoxazolyl group Chemical group 0.000 claims 2
125000004433 nitrogen atom Chemical group N* 0.000 claims 2
239000002777 nucleoside Substances 0.000 claims 2
150000003833 nucleoside derivatives Chemical class 0.000 claims 2
239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
229940122440 HIV protease inhibitor Drugs 0.000 claims 1
241000124008 Mammalia Species 0.000 claims 1
125000005160 aryl oxy alkyl group Chemical group 0.000 claims 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000005343 heterocyclic alkyl group Chemical group 0.000 claims 1
208000015181 infectious disease Diseases 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000003981 vehicle Substances 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000010189 synthetic method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Thiazole And Isothizaole Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Indole Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

OA1200300323A 2001-06-11 2002-06-11 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis. OA12697A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29746001P	2001-06-11	2001-06-11
US29772901P	2001-06-12	2001-06-12

Publications (1)

Publication Number	Publication Date
OA12697A true OA12697A (en)	2006-06-21

Family

ID=26970163

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
OA1200300323A OA12697A (en)	2001-06-11	2002-06-11	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
OA1200300322A OA12696A (en)	2001-06-11	2002-06-11	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
OA1200300322A OA12696A (en)	2001-06-11	2002-06-11	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

Country Status (27)

Country	Link
US (4)	US6953858B2 (fr)
EP (3)	EP1739082A1 (fr)
JP (2)	JP2005508867A (fr)
KR (2)	KR20040035601A (fr)
CN (2)	CN1599729A (fr)
AP (2)	AP1770A (fr)
AR (2)	AR036093A1 (fr)
AU (2)	AU2002316235A2 (fr)
BR (2)	BR0210344A (fr)
CA (2)	CA2450265A1 (fr)
EA (2)	EA200400023A1 (fr)
GE (1)	GEP20063890B (fr)
HN (1)	HN2002000136A (fr)
HR (2)	HRP20031015A2 (fr)
IL (2)	IL159076A0 (fr)
IS (2)	IS7050A (fr)
MA (2)	MA27347A1 (fr)
MX (2)	MXPA03011336A (fr)
NO (2)	NO20035489D0 (fr)
NZ (2)	NZ530023A (fr)
OA (2)	OA12697A (fr)
PA (2)	PA8547501A1 (fr)
PE (2)	PE20040479A1 (fr)
PL (1)	PL366622A1 (fr)
TN (1)	TNSN03130A1 (fr)
TW (1)	TW200538447A (fr)
WO (2)	WO2002100844A2 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094909B2 (en)	2001-06-11	2006-08-22	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US7169932B2 (en) *	2001-06-11	2007-01-30	Pfizer Inc.	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
HN2002000136A (es)	2001-06-11	2003-07-31	Basf Ag	Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
JP2006076882A (ja) *	2002-09-13	2006-03-23	Sumitomo Pharmaceut Co Ltd	新規なジペプチド化合物及びその医薬用途
WO2005026114A1 (fr) *	2003-09-17	2005-03-24	Pfizer Inc.	Inhibiteurs de la protease du vih, compositions les contenant et leurs utilisations pharmaceutiques
AU2004295187A1 (en) *	2003-12-04	2005-06-16	Pfizer Inc.	Methods for the preparation of stereoisomerically enriched amines
EP1692104A1 (fr) *	2003-12-04	2006-08-23	Pfizer Inc.	Procedes pour preparer des composes utiles en tant qu'inhibiteurs de la protease
JP2007513142A (ja) *	2003-12-04	2007-05-24	ファイザーインコーポレイテッド	プロテアーゼ阻害剤として有用な化合物の製造法
BRPI0417492A (pt) *	2003-12-09	2007-05-29	Pfizer	composições compreendendo um inibidor de protease de hiv
CA2555173A1 (fr) *	2004-01-30	2005-09-09	Pfizer Inc.	Compositions contenant un inhibiteur de la protease de vih et un inhibiteur de l'activite de l'enzyme du cytochrome p450
EP1713470A1 (fr) *	2004-01-30	2006-10-25	Pfizer, Inc.	Combinaisons therapeutiques
WO2005121094A1 (fr) *	2004-06-09	2005-12-22	Pfizer Limited	Derives de piperazine et de piperidine utilises comme agents anti-vih
CN103748059A (zh) *	2011-05-13	2014-04-23	弗特克斯药品有限公司	制备蛋白酶抑制剂的方法
KR102668696B1 (ko) *	2012-01-12	2024-05-29	예일 유니버시티	E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en)	2014-08-11	2018-09-11	Yale University	Estrogen-related receptor alpha based protac compounds and associated methods of use
US12312316B2 (en)	2015-01-20	2025-05-27	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of androgen receptor
JP6817962B2 (ja)	2015-01-20	2021-01-20	アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓＯｐｅｒａｔｉｏｎｓ，Ｉｎｃ．	ターゲティングされたアンドロゲン受容体分解のための化合物および方法
EP3270917A4 (fr)	2015-03-18	2018-08-08	Arvinas, Inc.	Composés et procédés de dégradation accrue de protéines ciblées
WO2016197114A1 (fr)	2015-06-05	2016-12-08	Arvinas, Inc.	Tank-binding kinase-1 protacs et procédés d'utilisation associés
GB201511382D0 (en)	2015-06-29	2015-08-12	Imp Innovations Ltd	Novel compounds and their use in therapy
US10772962B2 (en)	2015-08-19	2020-09-15	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of bromodomain-containing proteins
BR112018008918A8 (pt)	2015-11-02	2019-02-26	Univ Yale	compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
US20170281784A1 (en)	2016-04-05	2017-10-05	Arvinas, Inc.	Protein-protein interaction inducing technology
US20180072711A1 (en)	2016-09-15	2018-03-15	Arvinas, Inc.	Indole derivatives as estrogen receptor degraders
CN110506039A (zh)	2016-10-11	2019-11-26	阿尔维纳斯股份有限公司	用于雄激素受体靶向降解的化合物和方法
MX2019005007A (es)	2016-11-01	2019-07-18	Arvinas Inc	Protac dirigidos a la proteína tau y métodos asociados de uso.
BR112019011200B1 (pt)	2016-12-01	2021-12-28	Arvinas Operations, Inc	Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
US11173211B2 (en)	2016-12-23	2021-11-16	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
KR20250117470A (ko)	2016-12-23	2025-08-04	아비나스 오퍼레이션스, 인코포레이티드	급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
US10806737B2 (en)	2016-12-23	2020-10-20	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
JP2020505327A (ja)	2016-12-23	2020-02-20	アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓＯｐｅｒａｔｉｏｎｓ，Ｉｎｃ．	Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
US11191741B2 (en)	2016-12-24	2021-12-07	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
BR112019015312A2 (pt)	2017-01-26	2020-03-10	Arvinas Operations, Inc.	Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
IL312367A (en)	2017-01-31	2024-06-01	Arvinas Operations Inc	Cereblon ligands and bifunctional compounds comprising the same
EP3710443A1 (fr)	2017-11-17	2020-09-23	Arvinas Operations, Inc.	Composés et procédés pour la dégradation ciblée de polypeptides de kinase 4 associés au récepteur de l'interleukine 1
US12539292B2 (en)	2018-04-01	2026-02-03	Arvinas Operations, Inc.	BRM targeting compounds and associated methods of use
WO2019195609A2 (fr)	2018-04-04	2019-10-10	Arvinas Operations, Inc.	Modulateurs de protéolyse et procédés d'utilisation associés
JP7297053B2 (ja)	2018-08-20	2023-06-23	アルビナス・オペレーションズ・インコーポレイテッド	神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
EP3999182A1 (fr)	2019-07-17	2022-05-25	Arvinas Operations, Inc.	Composés ciblant la protéine tau et procédés d'utilisation associés
KR20220054347A (ko)	2019-08-26	2022-05-02	아비나스 오퍼레이션스, 인코포레이티드	에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
CN112574201B (zh) *	2019-09-29	2024-04-19	四川科伦博泰生物医药股份有限公司	芳基胺类化合物、包含其的药物组合物及其制备方法和用途
CN110803996B (zh) *	2019-11-13	2022-01-11	台州市创源工业技术有限公司	一种羟基苄胺的合成方法
AU2020405129A1 (en)	2019-12-19	2022-06-23	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of androgen receptor
US20230157998A1 (en)	2020-03-06	2023-05-25	Pfizer Inc.	Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
CR20220630A (es)	2020-05-09	2023-01-23	Arvinas Operations Inc	Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
WO2022047145A1 (fr)	2020-08-28	2022-03-03	Arvinas Operations, Inc.	Composés de dégradation de protéine de fibrosarcome rapidement accéléré et leurs procédés d'utilisation
WO2022056368A1 (fr)	2020-09-14	2022-03-17	Arvinas Operations, Inc.	Formes cristallines d'un composé pour la dégradation ciblée du récepteur des œstrogènes
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors
WO2024054591A1 (fr)	2022-09-07	2024-03-14	Arvinas Operations, Inc.	Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés
WO2024052685A1 (fr)	2022-09-09	2024-03-14	MyricX Pharma Limited	Composés imidazo[1,2-a]pyridine cytotoxiques et leur utilisation en thérapie
US12448399B2 (en)	2023-01-26	2025-10-21	Arvinas Operations, Inc.	Cereblon-based KRAS degrading PROTACs and uses related thereto
TW202535392A (zh)	2023-12-08	2025-09-16	美商亞文納營運公司	使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6418260A (en) *	1987-07-14	1989-01-23	Sanyo Electric Co	Transistor
US6313094B1 (en) *	1990-12-11	2001-11-06	Japan Energy Corporation	β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
CA2056911C (fr)	1990-12-11	1998-09-22	Yuuichi Nagano	Inhibiteurs de la protease de vih
CA2060844A1 (fr)	1991-02-08	1992-08-09	Yabe Yuichiro	Acides beta-amino-alpha-hydroxycarboxyliques et leur utilisation
ZA929869B (en)	1991-12-20	1994-06-20	Syntex Inc	Hiv protease inhibitors
US5644028A (en)	1992-05-13	1997-07-01	Japan Energy Corporation	Process for producing peptide derivatives and salts therefor
DE69322127T2 (de)	1992-05-13	1999-06-24	Japan Energy Corp., Tokio/Tokyo	Verfahren zur Herstellung von Peptidderivaten und ihrer Salze
NZ248332A (en)	1992-08-07	1995-01-27	Sankyo Co	Hiv protease inhibitor and its use
US5484926A (en)	1993-10-07	1996-01-16	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
EP0706794B1 (fr) *	1994-10-14	2001-12-12	Japan Energy Corporation	Composition pharmaceutique anti-SIDA et procédé de préparation
JPH08259532A (ja)	1995-03-24	1996-10-08	Japan Energy Corp	ペプチド様化合物又はその薬理的に許容される塩
CA2179935C (fr)	1995-06-30	2010-09-07	Ryohei Kato	Compose dipeptidique ou sel de ce dernier acceptable en pharmacie; utilisation en medecine
US6222043B1 (en)	1995-06-30	2001-04-24	Japan Energy Corporation	Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
JPH1087489A (ja)	1996-09-13	1998-04-07	Sankyo Co Ltd	Ａｈｐｂａ構造含有ジペプチド化合物を有効成分とする医薬
JPH10101654A (ja)	1996-10-02	1998-04-21	Japan Energy Corp	新規なジペプチド化合物又はその薬理的に許容される塩及びその医薬用途
JPH10182601A (ja) *	1996-12-27	1998-07-07	Japan Energy Corp	新規なジペプチド化合物又はその薬理的に許容される塩及びその医薬用途
AR012374A1 (es)	1997-04-15	2000-10-18	Smithkline Beecham Corp	Inhibidores de proteasas, composiones farmaceuticas y usos para la preparacion de medicamentos.
US6673772B2 (en)	1999-01-14	2004-01-06	Sumitomo Pharmaceuticals Company Limited	Dipeptide compounds and their use as antiviral agents
EP1155009A2 (fr)	1999-02-19	2001-11-21	Oklahoma Medical Research Foundation	Inhibiteurs de protease surmontant la resistance medicamenteuse
HN2002000136A (es)	2001-06-11	2003-07-31	Basf Ag	Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
WO2003035650A1 (fr)	2001-09-25	2003-05-01	Takeda Chemical Industries, Ltd.	Inhibiteur d'entree
JP2003119137A (ja)	2001-10-10	2003-04-23	Japan Tobacco Inc	Ｈｉｖ阻害剤
ATE355064T1 (de)	2001-10-26	2006-03-15	Angeletti P Ist Richerche Bio	Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
AU2002349675A1 (en)	2001-12-05	2003-06-17	Shionogi And Co., Ltd.	Derivative having hiv integrase inhibitory activity
CA2469592C (fr)	2001-12-12	2005-08-23	Bristol-Myers Squibb Company	Inhibiteurs de l'integrase du vih
EP1467970B1 (fr)	2002-01-17	2007-08-22	Merck & Co., Inc.	Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih
TW200306192A (en)	2002-01-18	2003-11-16	Bristol Myers Squibb Co	Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
WO2005026114A1 (fr) *	2003-09-17	2005-03-24	Pfizer Inc.	Inhibiteurs de la protease du vih, compositions les contenant et leurs utilisations pharmaceutiques
EP1692104A1 (fr) *	2003-12-04	2006-08-23	Pfizer Inc.	Procedes pour preparer des composes utiles en tant qu'inhibiteurs de la protease

2002
- 2002-06-10 HN HN2002000136A patent/HN2002000136A/es unknown
- 2002-06-11 EP EP06020180A patent/EP1739082A1/fr not_active Withdrawn
- 2002-06-11 US US10/166,957 patent/US6953858B2/en not_active Expired - Fee Related
- 2002-06-11 CN CNA028133455A patent/CN1599729A/zh active Pending
- 2002-06-11 HR HR20031015A patent/HRP20031015A2/hr not_active Application Discontinuation
- 2002-06-11 CA CA002450265A patent/CA2450265A1/fr not_active Abandoned
- 2002-06-11 BR BR0210344-3A patent/BR0210344A/pt not_active IP Right Cessation
- 2002-06-11 JP JP2003503613A patent/JP2005508867A/ja active Pending
- 2002-06-11 PA PA20028547501A patent/PA8547501A1/es unknown
- 2002-06-11 OA OA1200300323A patent/OA12697A/en unknown
- 2002-06-11 KR KR10-2003-7016114A patent/KR20040035601A/ko not_active Withdrawn
- 2002-06-11 EA EA200400023A patent/EA200400023A1/ru unknown
- 2002-06-11 WO PCT/US2002/018717 patent/WO2002100844A2/fr not_active Ceased
- 2002-06-11 NZ NZ530023A patent/NZ530023A/en unknown
- 2002-06-11 AU AU2002316235A patent/AU2002316235A2/en not_active Abandoned
- 2002-06-11 MX MXPA03011336A patent/MXPA03011336A/es active IP Right Grant
- 2002-06-11 EA EA200400026A patent/EA008169B1/ru not_active IP Right Cessation
- 2002-06-11 US US10/166,979 patent/US7179918B2/en not_active Expired - Fee Related
- 2002-06-11 IL IL15907602A patent/IL159076A0/xx unknown
- 2002-06-11 AP APAP/P/2003/002916A patent/AP1770A/en active
- 2002-06-11 CN CNB028132513A patent/CN100338044C/zh not_active Expired - Fee Related
- 2002-06-11 KR KR10-2003-7016171A patent/KR20040023616A/ko not_active Ceased
- 2002-06-11 CA CA002450269A patent/CA2450269A1/fr not_active Abandoned
- 2002-06-11 PA PA20028547601A patent/PA8547601A1/es unknown
- 2002-06-11 PL PL02366622A patent/PL366622A1/xx not_active Application Discontinuation
- 2002-06-11 NZ NZ530024A patent/NZ530024A/en unknown
- 2002-06-11 JP JP2003503612A patent/JP2004534061A/ja active Pending
- 2002-06-11 TN TNPCT/US2002/018717A patent/TNSN03130A1/fr unknown
- 2002-06-11 WO PCT/US2002/018548 patent/WO2002100845A1/fr not_active Ceased
- 2002-06-11 MX MXPA03011397A patent/MXPA03011397A/es unknown
- 2002-06-11 EP EP02744295A patent/EP1448539A1/fr not_active Withdrawn
- 2002-06-11 OA OA1200300322A patent/OA12696A/en unknown
- 2002-06-11 GE GE5419A patent/GEP20063890B/en unknown
- 2002-06-11 BR BR0210358-3A patent/BR0210358A/pt not_active IP Right Cessation
- 2002-06-11 AR ARP020102190A patent/AR036093A1/es unknown
- 2002-06-11 HR HR20031014A patent/HRP20031014A2/hr not_active Application Discontinuation
- 2002-06-11 AU AU2002345644A patent/AU2002345644B2/en not_active Ceased
- 2002-06-11 IL IL15902202A patent/IL159022A0/xx unknown
- 2002-06-11 AR ARP020102189A patent/AR036046A1/es unknown
- 2002-06-11 TW TW094121179A patent/TW200538447A/zh unknown
- 2002-06-11 AP APAP/P/2003/002915A patent/AP2003002915A0/en unknown
- 2002-06-11 EP EP02746518A patent/EP1409466A2/fr not_active Withdrawn
- 2002-06-14 PE PE2002000512A patent/PE20040479A1/es not_active Application Discontinuation
- 2002-06-14 PE PE2002000513A patent/PE20040241A1/es not_active Application Discontinuation
2003
- 2003-11-21 IS IS7050A patent/IS7050A/is unknown
- 2003-11-21 IS IS7049A patent/IS7049A/is unknown
- 2003-12-04 MA MA27423A patent/MA27347A1/fr unknown
- 2003-12-04 MA MA27424A patent/MA27348A1/fr unknown
- 2003-12-10 NO NO20035489A patent/NO20035489D0/no not_active Application Discontinuation
- 2003-12-10 NO NO20035488A patent/NO20035488D0/no unknown
2005
- 2005-06-20 US US11/155,568 patent/US20050250707A1/en not_active Abandoned
2006
- 2006-06-09 US US11/450,943 patent/US20070021354A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NZ530023A (en)	2005-10-28
AR036046A1 (es)	2004-08-04
MXPA03011336A (es)	2004-12-06
BR0210344A (pt)	2004-07-13
PA8547501A1 (es)	2003-02-14
GEP20063890B (en)	2006-08-10
PE20040241A1 (es)	2004-04-26
KR20040035601A (ko)	2004-04-29
PA8547601A1 (es)	2003-12-30
WO2002100845A8 (fr)	2003-03-20
US7179918B2 (en)	2007-02-20
OA12696A (en)	2006-06-22
MA27348A1 (fr)	2005-06-01
AP2003002916A0 (en)	2003-12-31
AP1770A (en)	2007-08-22
EA200400023A1 (ru)	2004-06-24
HN2002000136A (es)	2003-07-31
WO2002100844A2 (fr)	2002-12-19
CN1622942A (zh)	2005-06-01
EP1448539A1 (fr)	2004-08-25
MXPA03011397A (es)	2005-03-07
MA27347A1 (fr)	2005-06-01
KR20040023616A (ko)	2004-03-18
CA2450269A1 (fr)	2002-12-19
EP1409466A2 (fr)	2004-04-21
HRP20031014A2 (en)	2005-10-31
CN100338044C (zh)	2007-09-19
CA2450265A1 (fr)	2002-12-19
US20030153507A1 (en)	2003-08-14
AR036093A1 (es)	2004-08-11
IL159022A0 (en)	2004-05-12
HRP20031015A2 (en)	2005-10-31
CN1599729A (zh)	2005-03-23
AU2002345644B2 (en)	2006-08-10
PE20040479A1 (es)	2004-09-20
US20050250707A1 (en)	2005-11-10
WO2002100845A1 (fr)	2002-12-19
IS7049A (is)	2003-11-21
IS7050A (is)	2003-11-21
EA200400026A1 (ru)	2004-04-29
US6953858B2 (en)	2005-10-11
BR0210358A (pt)	2004-06-22
PL366622A1 (en)	2005-02-07
US20070021354A1 (en)	2007-01-25
AP2003002915A0 (en)	2003-12-31
AU2002345644A2 (en)	2002-12-23
TNSN03130A1 (fr)	2005-12-23
IL159076A0 (en)	2004-05-12
AU2002316235A2 (en)	2002-12-23
EP1739082A1 (fr)	2007-01-03
NZ530024A (en)	2005-10-28
US20030225071A1 (en)	2003-12-04
NO20035489D0 (no)	2003-12-10
AU2002345644C1 (en)	2002-12-23
JP2005508867A (ja)	2005-04-07
EA008169B1 (ru)	2007-04-27
TW200538447A (en)	2005-12-01
WO2002100844A3 (fr)	2003-03-06
NO20035488D0 (no)	2003-12-10
JP2004534061A (ja)	2004-11-11

Publication	Publication Date	Title
OA12697A (en)	2006-06-21	HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
RU2409576C2 (ru)	2011-01-20	Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
ME00876B (me)	2012-06-20	4"supstituisani-9-deokso-9a-aza-9a-homoeritromicin a derivati
RU2005137276A (ru)	2006-07-27	Замещенные дигидрохиназолины с противовирусными свойствами
RU2001108591A (ru)	2003-07-10	Арилпиперазины и их применение в качестве агентов-ингибиторов металлопротеиназ (ммр)
RU2005141553A (ru)	2006-07-27	Тригетероциклические соединения, композиции и способы лечения рака или вирусных заболеваний
ATE262327T1 (de)	2004-04-15	Verwendung von verbindungen zur erhöhung der pyruvatdehydrogenaseaktivität
JP2006506443A5 (fr)	2006-10-12
CA2672652A1 (fr)	2008-06-26	Composes d'azaquinolone possedant une activite inhibitrice de prolyl hydroxylase, compositions et utilisations correspondantes
ATE311358T1 (de)	2005-12-15	Immunoregulierende verbindungen, deren derivate und ihre verwendung
DE69011569D1 (de)	1994-09-22	Verbindungen der 1-Azabicyclo(3.2.0)hept-2-en-2-carbonsäure.
AU2736088A (en)	1989-06-29	Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
CA2539349A1 (fr)	2005-04-14	Naphtyridones et quinolones 7-amino alkylidenyl-heterocycliques
RU2007106930A (ru)	2008-09-10	Производные хиназолина
RU96116993A (ru)	1998-12-10	Новые фенилимидазолидины, в случае необходимости замещенные; способ их получения и получения промежуточных соединений; их применение в качестве лекарственных средств и содержащие их фармацевтические композиции
AU581324B2 (en)	1989-02-16	Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
CA2566541A1 (fr)	2005-12-22	Nucleosides 3-beta-d-ribofuranosylthiazolo[4,5-d]pyrimidiniques et leurs utilisations
US6423720B1 (en)	2002-07-23	Pyrimidine compounds and methods for making and using the same
WO2004075858A3 (fr)	2005-01-20	Composes analogues de l'acide flavone acetique et leurs procedes d'utilisation
EP1928884A4 (fr)	2008-11-12	Derives de 5,6-dimethyl[2,3-di]pyrimidine, leurs procede de preparation et composition pharmaceutique les comportant pour un traitement antiviral
WO2009142827A4 (fr)	2010-09-23	Composés et procédés destinés au traitement d'une infection virale
CA2453991A1 (fr)	2003-01-30	Nouveaux derives antitumoraux de et-743
WO2002074777A3 (fr)	2002-12-19	Composes pyranocoumariniques utilises en tant que nouveau pharmacophore ayant une activite anti-tb
CA2531766A1 (fr)	2005-03-17	Inhibiteurs de la penetration du virus vih
CA2322327A1 (fr)	1999-09-10	Traitement des infections virales porcines